arrow
G

Gaurav Chatterjee

Tata Memorial Hospital
H指数:20
被引数:1,467

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Is Less “Sufficient” and “Safe” in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma

在微小残留病时代,更少的剂量是否“足够”且“安全”?——根据美法仑剂量评估多发性骨髓瘤患者自体干细胞移植的结局

2026-01-080
OAAI
Attrition Rates in Multiple Myeloma - A Report from indian Patients at A Tertiary Cancer Center

多发性骨髓瘤患者的流失率——来自印度某三级癌症中心的患者报告

2025-12-010
OAAI
Treatment free remission (TFR) in chronic myeloid leukemia—results, compliance and patterns of failure from a tertiary care cancer centre in India

慢性髓性白血病中的无治疗缓解(TFR)——来自印度一家三级护理癌症中心的结果、依从性及失败模式

2025-10-310
OA
Prevalence and Prognostic Impact of NPM1 mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India

NPM1突变在儿童急性髓系白血病中的患病率及预后影响:来自印度一家三级癌症中心的经验

2025-10-210
PRE
Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort

慢性粒细胞白血病 (CML) 儿童的无治疗缓解: 来自塔塔纪念医院 (TMH) 儿科CML (pCML) 队列的前瞻性研究

2024-11-200
OAAI
Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
2024-04-010
OAAI
Treating relapsed B cell-precursor ALL in children with a setting-adapted mitoxantrone-based intensive chemotherapy protocol (TMH rALL-18 PROTOCOL) - experience from Tata Memorial Hospital, India
2023-07-210
PRE
P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.

P454: 具有IDH1和IDH2突变的急性髓系白血病(AML)可根据不良风险基因组特征的存在进行有效风险分层。

2023-01-010
OA
Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India
2022-03-019
OAAI
Comprehensive immune cell profiling depicts an early immune response associated with severe coronavirus disease 2019 in cancer patients
2021-10-278
OAAI
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
LEUKEMIA
IF13.4
2021-02-0864
OAAI
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
2020-05-2035
OAAI
NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies
2020-05-0512
OAAI
Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients
2020-04-2418
OAAI
A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1
2019-10-0116
OAAI
Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context
2019-06-1317
OAAI